Isuzinaxib is under clinical development by AptaBio Therapeutics and currently in Phase II for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase II drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Isuzinaxib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Isuzinaxib overview
Isuzinaxib (APX-115) is under development for the treatment of diabetic nephropathy, non-alcoholic steatohepatitis (NASH), coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and contrast-induced acute kidney injury (CI-AKI). It is a small molecule that is administered through oral route as capsule formulation. It acts by targeting pan-NADPH oxidase (NOX). The drug candidate is developed based on high throughout NOX screening technology.
AptaBio Therapeutics overview
AptaBio Therapeutics (AptaBio) is a biopharmaceutical company that develops platform based drugs for intractable diseases. Its product portfolio includes transfection reagents such as lipofector-EXT, lipofector-2000, lipofector-EZ and lipofector-pMAX. The company develops drugs based on NOX inhibitor discovery platform and Apta-DC platform technology. AptaBio’s product pipeline includes diabetic complications such as diabetic nephropathy, macular degeneration, diabetic retinopathy, arteriosclerosis, brain disease and anti-cancer drugs such as pancreatic-bladder and liver cancer. It partners with universities, hospitals, contract research organization, and contract manufacturing organization for drug development. AptaBio is headquartered in Yongin-SI, Gyeonggi-do, Republic of Korea.
For a complete picture of Isuzinaxib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
